ABSTRACT
Asthma is one of the most common chronic respiratory diseases in the world and there is great concern about the effect of COVID-19 infection on asthma severity and control. Although the link between asthma and COVID-19 infection remains to be determined, available data indicate that asthma does not seem to be a risk factor for severe COVID-19. This review aims to summarize the updated data about the association between viral infections and asthma exacerbations including COVID infection and management of asthma flare-ups during the COVID pandemic, based on the recommended asthma guidelines.Copyright © 2020 Bilimsel Tip Yayinevi. All rights reserved.
ABSTRACT
Aim: The pandemic period has led to social and individual behavioral changes all over the world. In this study, the differences in the admissions of non-coronavirus disease 2019 (non-COVID-19) community-acquired pneumonia cases during the pandemic lockdown period in Turkey were analyzed. Material(s) and Method(s): Patients with suspected COVID-19 and under the age of 18 were excluded, and non-COVID-19, hospitalized community-acquired pneumonia cases were included in this retrospective, cohort study. The analyzes were carried out by creating two groups as before the pandemic (March-May 2019) and the lockdown period of the pandemic (March-May 2020). The number of admissions and mortality rates were taken into consideration as primary outcomes. Result(s): There were 178 cases in the 2019 group and 63 cases in the 2020 group. Gender and age distribution were similar in these two groups. While the rate of intensive care hospitalization was high in the 2020 group, mortality was low (14.3% vs 19.1%);but these differences were not statistically significant. In addition, bilateral infiltration rates were significantly higher in the 2019 group (80.9% vs. 22.2%;p<0.001). Discussion(s): The low number of admissions during the lockdown period shows that there is awareness of the pandemic in society. Again, it can be said that this closure process plays a role in reducing the transmission of infectious diseases such as pneumonia.Copyright © 2022, Derman Medical Publishing. All rights reserved.
ABSTRACT
OBJECTIVE: COVID-19 may cause thrombosis in both venous and arterial systems. Familiarity with the signs and symptoms of thrombosis and its treatment is essential in treating COVID-19 infection and its complications. D-Dimer and mean platelet volume (MPV) are measurements related to the development of thrombosis. This study investigates whether MPV and D-Dimer values could be used to determine the risk of thrombosis and mortality in the COVID-19 early stages. PATIENTS AND METHODS: 424 patients who were COVID-19 positive, according to the World Health Organization (WHO) guidelines, were randomly and retrospectively included in the study. Demographic and clinical characteristics such as age, gender, and length of hospitalization were obtained from the digital records of participants. Participants were divided into living and deceased groups. The patients' biochemical, hormonal, and hematological parameters were analyzed retrospectively. RESULTS: White blood cells (WBC), neutrophils, and monocytes were significantly different in the two groups (p-value <0.001), and their values were lower in the living group than in the deceased group. MPV median values did not differ according to prognosis (p-value = 0.994). While the median value was 9.9 in the survivors, it was 10 in the deceased. Creatinine, procalcitonin, ferritin, and the number of hospitalization days in living patients were significantly lower than in patients who died (p-value <0.001). Median values of D-dimer (mg/L) differ according to prognosis (p-value <0.001). While the median value was 0.63 in the survivors, it was found as 438 in the deceased. CONCLUSIONS: Our results did not show any significant relationship between the mortality of COVID-19 patients and their MPV levels. However, a significant association between D-Dimer and mortality in COVID-19 patients was observed.
Subject(s)
COVID-19 , Thrombosis , Humans , Mean Platelet Volume , Prognosis , Retrospective StudiesABSTRACT
SUMMARY: Hypersensitivity reactions has been reported with COVID-19 vaccines. Acute eosinophilic pneumonia has not been reported yet after Sinovac/CoronaVac vaccine. A 73-year-old woman presented with maculopapular rash, cough and dyspnea following Sinovac/CoronaVac injection. The complete blood count (CBC) indicated eosinophilia and further evaluation of the eosinophilia with CT and bronchoscopy confirmed a diagnosis of acute eosinophilic pneumonia. After methylprednisolone therapy, her rash resolved with marked improvement of the dyspnea. She is still on treatment and on the follow up period, we plan to continue steroid treatment at least 3 months.
ABSTRACT
Objective: To investigate the clinical symptoms of coronavirus disease 2019 (COVID-19) patients with and without B.1.1.7 mutation. Method(s): This retrospective observational study included COVID-19 patients who were divided into two groups, the mutation and the non-mutation group. Demographics characteristics, clinical characteristics, laboratory parameters, and mortality rates were recorded and compared between the two groups. Result(s): A total of 196 patients were included in the study. The relationship between the mutant virus status and sex, age, comorbidity, survival status, and disease severity was not significant (P>0.05). No significant differences were found in duration of hospitalization between the mutation and the non-mutation group (P>0.05). However, there was a statistically significant difference between patients with and without mutant viruses in hemoglobin, mean platelet volume, procalcitonin, low density lipoprotein, ironbinding capacity, potassium, calcium, C-reactive protein, folate, creatine kinase myocardial band, D-dimer, and international normalized ratio (P<0.05). Conclusion(s): No significant difference is found in mortality rate, disease severity or duration of hospitalization between the patients with and without variant B.1.1.7. Careful monitoring of COVID-19 patients is required for all variants. Copyright ©2022 Journal of Acute Disease Produced by Wolters Kluwer-Medknow.
ABSTRACT
OBJECTIVE: Our study aimed at investigating the impacts of demographic, hematological, and biochemical factors on the clinical course and the prognostic outcome in adult COVID-19 patients. PATIENTS AND METHODS: This retrospective study was performed in the internal medicine departments of two hospitals, and data were extracted from the medical files of 1,700 adult COVID-19 patients (836 females, 49.2%; 864 males, 50.8%) with an average age of 48.23 ± 16.68 (range: 18-93). Clinical data included baseline descriptives, prior medical history, admission date, treatment, and hematological and biochemical blood test results. The relationship between the survival, length of hospitalization, hematological, and biochemical parameters was investigated. RESULTS: Advanced age (p<0.001), presence of at least on comorbid disease (p=0.045), increased length of hospitalization (p=0.006), elevated white blood cell (p=0.001) and neutrophil (p=0.002) counts, increased serum levels of glucose (p=0.027), blood urea nitrogen (p<0.001), AST (p=0.006), LDH (p<0.001), CRP (p>0.001), and D-dimer (p=0.001). In contrast, diminution of serum levels of albumin (p<0.001), ALT (p=0.028), calcium (p=0.022), and platelet count (p=0.010) were associated with increased mortality. There was a positive and weak relationship between serum D-dimer levels and length of hospitalization. CONCLUSIONS: Our data imply that identifying and validating indicators that predict COVID-19 disease progression to improve health outcomes is crucial. Age, comorbidities, immunological response, radiographic abnormalities, laboratory markers, and signs of organ dysfunction may all predict poor outcomes individually or collectively. Identifying characteristics that predict COVID-19 problems is critical to guiding clinical management, improving patient outcomes, and allocating limited resources.
Subject(s)
COVID-19 , Male , Adult , Female , Humans , Middle Aged , COVID-19/therapy , Retrospective Studies , Severity of Illness Index , Prognosis , Treatment OutcomeABSTRACT
Aim: The pandemic period has led to social and individual behavioral changes all over the world. In this study, the differences in the admissions of non-coronavirus disease 2019 (non-COVID-19) community-acquired pneumonia cases during the pandemic lockdown period in Turkey were analyzed.Material and Methods: Patients with suspected COVID-19 and under the age of 18 were excluded, and non-COVID-19, hospitalized community-acquired pneumonia cases were included in this retrospective, cohort study. The analyzes were carried out by creating two groups as before the pandemic (March-May 2019) and the lockdown period of the pandemic (March-May 2020). The number of admissions and mortality rates were taken into consideration as primary outcomes.Results: There were 178 cases in the 2019 group and 63 cases in the 2020 group. Gender and age distribution were similar in these two groups. While the rate of intensive care hospitalization was high in the 2020 group, mortality was low (14.3% vs 19.1%);but these differences were not statistically significant. In addition, bilateral infiltration rates were significantly higher in the 2019 group (80.9% vs. 22.2%;p<0.001).Discussion: The low number of admissions during the lockdown period shows that there is awareness of the pandemic in society. Again, it can be said that this closure process plays a role in reducing the transmission of infectious diseases such as pneumonia.
ABSTRACT
PURPOSE OF THE STUDY As in orthopedic trauma patients, a hyperinflammatory response due to cytokine release occurs in patients with moderate and severe COVID-19 infection. In these patients, untimely surgical intervention can create more destructive situations in the postoperative period. Our aim in this study was to investigate the effect of COVID-19, trauma and surgical intervention on acute phase reactants' levels in patients with and without COVID-19 infection. MATERIAL AND METHODS Twenty-four patients diagnosed with COVID-19 infection and major fractures requiring surgical treatment were evaluated retrospectively (Group 1). Twenty-four COVID-19 negative patients with similar trauma were included in the study as a control group (Group 2). These two groups were compared in terms of demographic data, time to surgery, total hospitalization time, and preoperative and postoperative acute phase reactants' [C-reactive protein (CRP), D-dimer, ferritin, fibrinogen and white blood cell (WBC)] values. RESULTS Time to surgery was 8.3 ± 0.7 days and the total hospital stay was 15.2 ± 0.8 days, in Group 1. These values were determined as 3.3 ± 0.4 and 6.5 ± 0.6 days, respectively for the patients in Group 2 (p < 0.001 and p < 0.001, respectively). When the acute phase reactant values studied during admission were examined, a significant difference was found between the two groups in terms of CRP, D-dimer, ferritin and WBC (p = 0009, p = 0.002, p < 0.001 and p < 0.001, respectively). In the preoperative period, a significant difference was observed between the groups in terms of CRP and ferritin (p = 0.011, p < 0.001, respectively). A significant difference was found only in terms of ferritin from the laboratory values studied in the postoperative period (p < 0.001). DISCUSSION To our knowledge, the present study is the first study which compares and investigates the effects of COVID-19 infection, major fracture and surgical intervention on acute phase reactants' values. Surgical treatment is generally recommended as soon as possible in daily orthopedic practice. However, in patients with asymptomatic or mildly symptomatic COVID-19 infection, it remains unclear how long surgical intervention will be delayed after admission and clinical stabilization of patients with a fracture that requires surgical fixation. In a meta-analysis, patients with COVID-19 infection accompanying hip fracture had a mortality rate of 32.6% in the early postoperative period, and the mortality risk of these patients was found to be 5.66 times higher compared to patients without COVID-19 infection. In our study, one patient (4.2%) with COVID-19 infection who underwent partial hip arthroplasty due to femoral neck fracture. CONCLUSIONS The follow-up and treatment of patients with COVID-19 infection with accompanying a major fracture requiring orthopedic surgery is a complex situation. We recommend that acute phase reactants such as CRP, D-dimer, erythrocyte sedimentation rate (ESR), and ferritin should be closely monitored in these patients during the period from admission to surgery, and surgical intervention should be performed while these values are in remission or decline. Key words: COVID-19, fracture, trauma, acute phase reactants, surgical timing.
ABSTRACT
This article analyses the Erdogan government's policy response to the coronavirus pandemic. Despite the abundant use of moral antagonisms in his discourse, Erdogan did not attempt to politicize the pandemic, instead framing it as a global health crisis and presenting the government's public health policies as expert-driven and competent. However, this expert-driven approach was largely a performance. Without a system of democratic oversight or a free media to scrutinize government policies, the Erdogan government could systematically undercount COVID-19 cases and disregard its own public health restrictions, all the while spreading its narrative of competence and success. Competitive policymaking by opposition-controlled municipalities and criticism from a strong doctors' association had relatively limited ability to discredit the government. The public opinion data we present reveal broad-based support for the government's COVID policies. Our article highlights how authoritarian institutions allow governments to sustain a gap between performance and actuality, granting their leaders greater possibilities to claim policy success.
ABSTRACT
PURPOSE OF THE STUDY As in orthopedic trauma patients, a hyperinflammatory response due to cytokine release occurs in patients with moderate and severe COVID-19 infection. In these patients, untimely surgical intervention can create more destructive situations in the postoperative period. Our aim in this study was to investigate the effect of COVID-19, trauma and surgical intervention on acute phase reactants' levels in patients with and without COVID-19 infection. MATERIAL AND METHODS Twenty-four patients diagnosed with COVID-19 infection and major fractures requiring surgical treatment were evaluated retrospectively (Group 1). Twenty-four COVID-19 negative patients with similar trauma were included in the study as a control group (Group 2). These two groups were compared in terms of demographic data, time to surgery, total hospitalization time, and preoperative and postoperative acute phase reactants' [C-reactive protein (CRP), D-dimer, ferritin, fibrinogen and white blood cell (WBC)] values. RESULTS Time to surgery was 8.3 +/- 0.7 days and the total hospital stay was 15.2 +/- 0.8 days, in Group 1. These values were determined as 3.3 +/- 0.4 and 6.5 +/- 0.6 days, respectively for the patients in Group 2 (p < 0.001 and p < 0.001, respectively). When the acute phase reactant values studied during admission were examined, a significant difference was found between the two groups in terms of CRP, D-dimer, ferritin and WBC (p = 0009, p = 0.002, p < 0.001 and p < 0.001, respectively). In the preoperative period, a significant difference was observed between the groups in terms of CRP and ferritin (p = 0.011, p < 0.001, respectively). A significant difference was found only in terms of ferritin from the laboratory values studied in the postoperative period (p < 0.001). DISCUSSION To our knowledge, the present study is the first study which compares and investigates the effects of COVID-19 infection, major fracture and surgical intervention on acute phase reactants' values. Surgical treatment is generally recommended as soon as possible in daily orthopedic practice. However, in patients with asymptomatic or mildly symptomatic COVID-19 infection, it remains unclear how long surgical intervention will be delayed after admission and clinical stabilization of patients with a fracture that requires surgical fixation. In a meta-analysis, patients with COVID-19 infection accompanying hip fracture had a mortality rate of 32.6% in the early postoperative period, and the mortality risk of these patients was found to be 5.66 times higher compared to patients without COVID-19 infection. In our study, one patient (4.2%) with COVID-19 infection who underwent partial hip arthroplasty due to femoral neck fracture. CONCLUSIONS The follow-up and treatment of patients with COVID-19 infection with accompanying a major fracture requiring orthopedic surgery is a complex situation. We recommend that acute phase reactants such as CRP, D-dimer, erythrocyte sedimentation rate (ESR), and ferritin should be closely monitored in these patients during the period from admission to surgery, and surgical intervention should be performed while these values are in remission or decline.
ABSTRACT
BACKGROUND AND AIM: Many studies have investigated whether A, B, and 0 blood groups are associated with COVID-19. In some of these studies, the relationship between these blood groups and COVID-19 susceptibility has been shown. Our study aimed to investigate whether there is a relationship between COVID-19 infection and AB0 blood groups. METHODS: 1000 patients who applied to Erbaa State Hospital between April 1, 2020, and April 1, 2021, and were diagnosed with COVID-19 were included in our study. The patients were evaluated retrospectively based on their blood group, gender, age, intensive care unit admission, intubation status, mortality, and having mutant variants. RESULTS: A blood group was the most common group in COVID-19 patients with 39.1%. Next was 0 (33.2%), B (16.1%), and AB (11.6%). A blood group was statistically significantly higher in COVID-19 patients compared to the healthy control group (32.3%) (p=0.004). The O blood group was significantly lower in COVID-19 patients than the control group (39.7%) (p=0.006). There was no significant difference between the groups in terms of Rh positivity and negativity. The mortality rate in COVID-19 patients was found to be 12.7%. The mortality rate was significantly higher in the 0 blood group than in the A blood group (OR=1.587, p=0.02). CONCLUSIONS: According to the results of our study, individuals with 0 blood group have a lower risk of contracting COVID-19 disease, but the mortality rate is higher. Individuals with the A blood group are more susceptible to COVID-19. Multicenter and more comprehensive studies are needed to better understand the prognostic and diagnostic importance of blood groups.
ABSTRACT
The COVID-19 coronavirus case has affected people's daily life as well as their consumption habits and behaviors. People have had to live an isolated life in their home. This situation has caused the traditional market concept, which is defined as the environment where buyers and sellers come together, to change. Buyers and sellers who could not come face to face in the market sought the solution on the digital platform. In particular, the development in mobile internet and technologies has led to further digitalization of the market and the consumer with the pandemic process. It is obvious that after the pandemic is over, consumers will have no difficulty in returning and adapting to the traditional marketing environment they miss. However, it would be a wrong prediction to mention that consumers who experience the digital environment and are aware of its convenience and benefits will leave the digital market completely. At the end of the pandemic process, a system that includes the dynamics of both traditional marketing and digital marketing awaits consumers and marketing practitioners. The name of this system and the new order can be called hybrid marketing. In this direction, the aim of the study is to reveal the hybrid 4P that awaits us after the pandemic by explaining how the 4P of marketing is digitalized during the pandemic process. © Peter Lang GmbH Internationaler Verlag der Wissenschaften Berlin 2021. All rights reserved.
ABSTRACT
In the ongoing COVID-19 pandemic, several patients have experienced respiratory failure, for which high-flow nasal oxygen therapy (HFNO) is a frequently preferred treatment modality. In the present study, three COVID-19 patients being followed up with HFNO in the intensive care unit underwent fiberoptic bronchoscopy, and a burned/wounded mucosa with widespread hyperemia, hyperpigmentation and mucosal damage throughout the entire tracheobronchial system mucosa was detected in all cases, the long-term effects of which are unknown. Herein, we aim to draw attention to the possible development of mucosal damage after HFNO, which should be kept in mind during the provision of ventilation support to COVID-19 patients.
ABSTRACT
BACKGROUND: Vitamin D has anti-inflammatory and immunomodulatory effects via the downregulation of pro-inflammatory cytokines. We aimed to demonstrate the effect of vitamin D levels on survival in COVID-19 patients. MATERIALS AND METHODS: 207 COVID-19 patients were included in the study. Serum vitamin D levels were measured, and patients with levels <20 ng/ml or 21 to 30 ng received a single 300.000 IU dose of vitamin D. RESULTS: Of 207 patients, 37 received vitamin D, while 170 did not. Demographic, radiologic and mean laboratory values were similar between the groups. The mean plasma vitamin D level without vitamin D support (n=170) was 50.82±16.12 ng/ml (30.28-81.35) vs. 16.98±6.2 ng/ml (4.20-28.30) in vitamin D group. The most remarkable finding were the mortality rates; while only 1 patient (2.7 %) died in the vitamin D group, 24 patients (14.1 %) died in no vitamin D supplementation group (p=0.038). CONCLUSION: Although a few retrospective studies put forth a relation between vitamin D deficiency and COVID-19 course severity there is still paucity of data about the efficacy of vitamin supplementations in COVID-19 patients. A single 300.000 IU dose of vitamin D seems to represent a useful, practical, and safe adjunctive approach for the treatment or prevention of COVID-19 (Tab. 1, Fig. 1, Ref. 30).
Subject(s)
COVID-19 , Vitamin D Deficiency , Humans , Prognosis , Retrospective Studies , SARS-CoV-2 , Vitamin D , Vitamin D Deficiency/complications , Vitamin D Deficiency/diagnosis , Vitamin D Deficiency/drug therapyABSTRACT
The outbreak of coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 infection has recently spread worldwide was declared a pandemic on March 11. The most common symptoms of COVID-19 disease are fever, fatigue, and dry cough. Some patients may experience pain and aches, nasal congestion, cold, sore throat or diarrhea. These symptoms are usually mild and begin gradually. Currently, the source of the virus is still unknown. However, all available evidence indicates that the origin of this virus is a natural animal and that it is not a manufactured virus. The virus spreads faster than its two ancestors the severe acute respiratory syndrome coronavirus and Middle East Respiratory Syndrome Coronavirus. The effects of COVID-19 disease on people are that the elderly and people with preexisting medical conditions (such as hypertension, heart disease, and diabetes) have more severe symptoms than others. Some potential vaccines and drugs specifically needed to treat this disease are being investigated and are being tested by clinical trials. Copyright © 2020 Wolters Kluwer Health, Inc. All rights reserved.
ABSTRACT
Nebulizers generate aerosols and may potentially transmit respiratory viral particles including SARS-CoV-2. There is a great concern about the use of a nebulizer in the treatment of asthma exacerbations in the hospital or home setting during the COVID-19 pandemic and its use is not recommended unless essential. However, aerosol therapy should not be avoided in obligatory indications. Therefore, indications of nebulizer use during the pandemic should be evaluated on an individual basis in case of a severe asthma attack, and infection control recommendations should be followed by clinicians while using nebulizers. In this article, we aimed to assess the safety in addition to the "pro" and "con" sides of nebulizer treatment in asthma exacerbation during the COVID-19 pandemic.
ABSTRACT
Corona virus disease-2019 (COVID-19) emerged in Wuhan, China in December 2019 and was declared as a pandemic by the World Health Organization in March 2020. Although there is no complete treatment protocol for COVID-19, studies on this topic are ongoing, and it is known that broad-spectrum antibiotics such as cephalosporins are used for coinfections and symptoms in COVID-19 patients. Studies have shown that Staphylococcus aureus and Escherichia coli bacteria can cause symptoms such as diarrhea and coinfections accompanying COVID-19. Therefore, in this study, colon-targeted cefaclor monohydrate (CEF)-loaded poly(lactic-co-glycolic acid) (PLGA)-Eudragit S100 nanoparticles (NPs) were prepared using a nanoprecipitation technique. The particle sizes of the CEF-loaded NPs were between 171.4 and 198.8 nm. The encapsulation efficiency was in the range of 58.4%-81.2%. With dissolution studies, it has been concluded that formulations prepared with Eudragit S100 (E-coded) and Eudragit S100+PLGA (EP-coded) are pH-sensitive formulations and they are targetable to the colon, whereas the formulation prepared only with PLGA (P-coded) can release a higher CEF rate in the colon owing to the slow release properties of PLGA. The release kinetics were fitted to the Korsmeyer-Peppas and Weibull models. The antibacterial activity of E-, EP-, and P-coded formulations was 16-fold, 16-fold, and 2-fold higher than CEF, respectively, for S. aureus and E. coli according to the microdilution results. As a result of the time killing experiment, all formulations prepared were found to be more effective than the antibiotic itself for long periods. Consequently, all formulations prepared in this study hope to guide researchers/clinicians in treating both gram-positive and gram-negative bacteria-induced infections, as well as COVID-19 associated coinfections and symptoms.
Subject(s)
Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/therapeutic use , Bacterial Infections/complications , Bacterial Infections/drug therapy , COVID-19/complications , Cefaclor/administration & dosage , Cefaclor/therapeutic use , Intestinal Diseases/complications , Intestinal Diseases/drug therapy , Anti-Bacterial Agents/pharmacology , Cefaclor/pharmacology , Coinfection , Drug Compounding , Escherichia coli/drug effects , Excipients , Kinetics , Microbial Sensitivity Tests , Nanoparticles , Particle Size , Polylactic Acid-Polyglycolic Acid Copolymer , Polymethacrylic Acids , Staphylococcus aureus/drug effectsABSTRACT
Aim: The aim of the present study was to evaluate the effect of the pandemic regulations on clinics of the Oral and Maxillofacial Surgery Department. Material and Methods: Patient data (age, gender, total patient number, total number of applied treatments and total income ) between March 16 and June 1, 2020 were evaluated and compared with the records of the previous two years. Results: Comparison of the number of patient treated showed a 90% decrease in 2020. In addition, the total number of applied treatment decreased by more than 90% in 2020. Additionally, the total income of the department decreased by 90% in 2020 compared to the previous two years. Discussion: The SARS-CoV-2 virus can transmit from human to human via airborne droplets or aerosol. Therefore, the dentist and the staff of a dental clinic or department are more likely to be infected with SARS-CoV-2 than the staff of any other health discipline. The COVID-19 pandemic has affected all people around the world, socially, economically, and psychologically. Governments must be economically prepared for such a situation.
ABSTRACT
Asthma is one of the most common chronic respiratory diseases in the world and there is great concern about the effect of COVID-19 infection on asthma severity and control. Although the link between asthma and COVID-19 infection remains to be determined, available data indicate that asthma does not seem to be a risk factor for severe COVID-19. This review aims to summarize the updated data about the association between viral infections and asthma exacerbations including COVID infection and management of asthma flare-ups during the COVID pandemic, based on the recommended asthma guidelines.
ABSTRACT
The most important factor in the transmission of the COVID-19 is asymptomatic carriers. We've tested all oncology patients , that receive anti-cancer therapy, for COVID-19. We aimed to determine the rate of asymptomatic carriers, and analyze the clinical and radiological findings of infected patients. Oncology patients who have indications of receiving anti-cancer treatment in the hospital were tested for COVID-19, two day prior to their treatment even if they were asymptomatic by collecting nasopharyngeal and oropharyngeal swab specimens for RT-PCR for viral RNA detection. Positive patients, underwent inspiratory phase of chest computed tomography examination. Infected patients were given the recommended treatment for COVID-19. PCR test was positive in 28 of 312 patients that we tested, and the positivity rate was 8.9%. Three patients (10.7%) had symptoms, 25 patients (89.3%) had no symptoms. Covid-19 testing before anti-cancer treatment may be recommended in order to continue their treatment without any problems and to prevent the risk of transmission due to the high rate of asymptomatics in infected patients.